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The GABAergic system in the central amygdala (CeA) plays a major role in ethanol
dependence and the anxiogenic-like response to ethanol withdrawal. A large body of
evidence shows that Nociceptin/Orphanin FQ (N/OFQ) regulates ethanol intake and
anxiety-like behavior. In the rat, ethanol significantly augments CeA GABA release,
whereas N/OFQ diminishes it. Using electrophysiological techniques in an in vitro
slice preparation, in this study we investigated the effects of a nonpeptidergic NOP
receptor agonist, MT-7716 [(R)-2-3-[1-(Acenaphthen-1-yl)piperidin-4-yl]-2-oxo-2,3-dihydro-
1H-benzimidazol-1-yl-N-methylacetamide hydrochloride hydrate], and its interaction with
ethanol on GABAergic transmission in CeA slices of naïve rats. We found that MT-
7716 dose-dependently (100–1000 nM) diminished evoked GABAA receptor-mediated
inhibitory postsynaptic potentials (IPSPs) and increased paired-pulse facilitation (PPF)
ratio of these evoked IPSPs, suggesting a presynaptic site of action of the MT-7716 by
decreasing GABA release at CeA synapses. The presynaptic action of MT-7716 was also
supported by the significant decrease in the frequency of miniature inhibitory postsynaptic
currents (mIPSCs) induced by the nociceptin receptor (NOP) agonist. Interestingly, MT-
7716 prevented the ethanol-induced augmentation of evoked IPSPs. A putative selective
NOP antagonist, [Nphe1]Nociceptin(1–13)NH2, totally prevented the MT-7716-induced
inhibition of IPSP amplitudes indicating that MT-7716 exerts its effect through NOPs.
These data provide support for an interaction between the nociceptin and GABAergic
systems in the CeA and for the anti-alcohol properties of the NOP activation. The
development of a synthetic nonpeptidergic NOP receptor agonist such as MT-7716 may
represent a useful therapeutic target for alcoholism.
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INTRODUCTION
Alcoholism is a chronically relapsing disorder characterized by
compulsive drug- seeking and taking (Koob and Le Moal, 1997).
It is one of the most prevalent health problems worldwide;
nevertheless there are very few medications available for treat-
ing it. Understanding the neurobiology of alcohol abuse and
addiction will strongly contribute to the development of effec-
tive new pharmacotherapies for alcoholism. Recently, a body of
research has been focused on the identification of new targets for
pharmacological treatments of alcohol addiction; among these,
several peptidergic systems known for their established role in the
regulation of stress response and anxiety-like behaviors associated
with the development of alcohol addiction.
Nociceptin/Orphanin FQ (N/OFQ) is an opioid-like peptide
(Meunier et al., 1995; Reinscheid et al., 1995; Meunier, 1997),
that acts at opioid-like receptors (Calo et al., 2000), although
it does not bind to classic opioid receptors. N/OFQ and other
NOP agonists have shown an anxiolytic-like profile in animal
studies (Jenck et al., 1997, 2000). It decreases alcohol drinking,
and prevents relapse-like behavior in rats (Ciccocioppo et al.,
2000, 2002b, 2004, 2007; Kuzmin et al., 2007; Ubaldi et al.,
2013).
Central intracranial injection of N/OFQ is demonstrated to
induce anxiolytic-like effects in several behavioral paradigms,
each generating different types of anxiety leading to the theory
that this peptide may act as an endogenous regulator of acute
anxiety. Studies in knockout animals have shown that geneti-
cally engineered nociceptin precursor-deficient mice display an
increased susceptibility to acute and repeated stress, as compared
to their wild-type littermates (Koster et al., 1999; Reinscheid et al.,
1999). Moreover, N/OFQ inhibits stress-induced ethanol seeking
and attenuates various extrahypothalamic effects of corticotropin
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releasing factor (CRF), the major mediator of stress in mam-
mals (Allison and Sheehy, 1992; Ciccocioppo et al., 2002a, 2004;
Martin-Fardon et al., 2010; Schank et al., 2012). In Wistar rats
with a history of ethanol dependence, neuroadaptive changes in
the N/OFQ system have been associated with increased stress
sensitivity and alcohol intake (Braconi et al., 2010; Aujla et al.,
2013), as well as a more pronounced anxiolytic effect of N/OFQ
in dependent rats in comparison to naïve rats. It has been well
documented that systemic administration of alcohol alters basal
levels of N/OFQ in several brain regions, as well as mRNA
expression in animals previously exposed to stress (Roberto and
Siggins, 2006; Higley et al., 2012). In addition to these evidences,
our laboratory has previously reported at the cellular level that
N/OFQ dose-dependently decreases evoked and spontaneous
GABAA-mediated transmission in the central amygdala (CeA)
decreasing presynaptic GABA release (Roberto and Siggins, 2006).
Importantly, in CeA from ethanol-dependent rats the N/OFQ-
induced decrease in CeA GABAergic transmission is larger than
that observed in naïve rats, suggesting that neuroadaptations
occur at these synapses during chronic alcohol exposure (Roberto
and Siggins, 2006). Notably, the CeA has been also identified as
the putative brain site of action of N/OFQ for its inhibitory effects
on ethanol drinking (Economidou et al., 2008).
Jenck et al. (2000) developed the first nonpeptidergic
brain-penetrant NOP receptor agonist, Ro 61-6198, that was
tested on alcohol-related behaviors (Kuzmin et al., 2007) and
(Economidou et al., 2006). Another small-molecule NOP agonist,
2-3-[1-((1R)-acenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-
oxo-benzimidazol-1-yl-N-methylacetamide (W-212393), was
synthesized by Teshima et al. (2005) and tested in rats on the
circadian body temperature rhythm of rats. Recently, a blood
brain barrier penetrating NOP receptor agonist MT-7716,
hydrochloride of W-212393 has become available, providing
a suitable pharmacological tool to study the treatment target
potential of the nociceptin system with direct translational
implications. MT-7716 has high affinity for human NOP
receptors expressed in HEK293 cells. The affinity of MT-7716
for the NOP is almost equal to that of the endogenous agonist
N/OFQ, and higher than that of other nonpeptidergic NOP
agonist, Ro 64-6198. NOP agonistic activities of MT-7716 were
evaluated by GTPγ35S binding to human NOP expressed in
HEK293 cells and the maximum effect was almost equal to that
of N/OFQ, suggesting that MT-7716 is a full agonist for NOP
receptors (Teshima personal communication).
Here, we investigated the effect of this novel molecule per se
on the CeA GABAergic transmission and its interaction with
acute ethanol application in CeA slices from naïve control rats.
Similar to our previous electrophysiological studies (Roberto
and Siggins, 2006; Cruz et al., 2012) on the characteriza-
tion of N/OFQ actions in rat CeA, we found that MT-7716
dose-dependently decreases GABAergic transmission and effec-
tively blocks the ethanol-induced increase in GABA release at
these synapses. Our studies provide insights in the underlying
mechanisms of MT-7716 effects on the GABAergic transmission
in the CeA and support the importance of developing nonpep-
tidergic NOP agonists, as valid pharmacological tools to treat
alcoholism.
MATERIALS AND METHODS
ANIMALS
Male Wistar rats (n = 70) (Charles River, Wilmington, MA, USA),
at the age of 8–12 weeks were used. Their body weight ranged
between 330 and 370 g at the time of slice-recordings. Rats were
housed two per cage in a room with reversed artificial 12:12 h
light/dark cycle (lights off at 8:00 A.M.) at constant temperature
(20–22◦C) and humidity (45–55◦), with ad libitum access to tap
water and food pellets (PJ Noyes Company, Inc., Lancaster, NH).
All procedures met the guidelines of The Scripps Research Institute
IACUC and NIH guidelines on the care and use of laboratory
animals.
ELECTROPHYSIOLOGICAL STUDIES
Slice preparation
CeA slices were prepared as previously described, (Roberto et al.,
2003, 2004b; Cruz et al., 2012), from rats anesthetized with
isoflurane (1–3%) and immediately decapitated. Transverse slices
were cut 300–400 µm thick on a Leica 1000S vibratome (Cam-
pden, Lafayette, Indiana). They were incubated in an interface
configuration for about 20 min, completely submerged and con-
tinuously superfused in cold gassed artificial cerebrospinal fluid
(ACSF) of the following composition (in mM): NaCl, 130; KCl,
3.5; NaH2PO4, 1.25; MgSO4•7H2O, 1.5; CaCl2, 2.0; NaHCO3,
24; glucose, 10. Drugs were added to the warm (31◦C) ACSF,
(flow rate of 2–4 ml/min) from stock solutions to obtain known
concentrations in the superfusate.
Intracellular recording of evoked responses
Recordings were performed from CeA neurons (from the
medial subdivision of the CeA) with sharp micropipettes
filled with 3M KCl using discontinuous current-clamp mode,
(Roberto et al., 2004b; Haubensak et al., 2010; Cruz et al.,
2012). Most neurons were held near their resting membrane
potential (RMP). Data were acquired with an Axoclamp-2A
preamplifier (Axon Instruments, Foster City, CA) and stored
for later analysis using pClamp software (Axon Instruments,
Foster City, CA). We evoked pharmacologically-isolated GABAA
receptor-mediated inhibitory postsynaptic potentials (IPSPs)
by stimulating locally within the CeA through a bipolar
stimulating electrode while superfusing the slices with the
glutamate receptor blockers 6,7-Dinitroquinoxaline-2, 3-dione
(DNQX; 20 µM) and DL-2-amino-5-phosphonovalerate
(APV; 30 µM), and the GABAB receptor antagonist ((3-N[1-
(S)-(3,4-Dichlorophenyl)ethyl]amino-2-(S)-hydroxypropyl)-
benzyl-phosphinic acid (CGP) 55845A; 1 µM). At the end
of the recording, superfusion with either 30 µM bicuculline
or 50 µM picrotoxin was routinely performed to confirm the
GABAAergic nature of the IPSPs. To determine the synaptic
response parameters for each cell, we performed an input-output
(I-O) protocol (Roberto et al., 2003, 2004b) consisting of a range
of five current stimulations (50–250 mA; 0.125 Hz), starting at
the threshold current required to elicit an IPSP up to the strength
required to elicit the maximum amplitude. These stimulus
strengths were maintained throughout the entire duration of the
experiment. In our graphs only the three middle intensities are
plotted. The synaptic responses were quantified by calculating
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the IPSP amplitude with Clampfit software (Axon Instruments).
The paired-pulse facilitation (PPF) in each neuron was examined
by using paired stimuli at 50 and 100 ms inter-stimulus interval
(Roberto et al., 2004b). The stimulus strength was adjusted
such that the amplitude of the first IPSP was 50% of maximal,
determined from the I-O relationship. The PPF ratio was
calculated as the second IPSP amplitude over that of the first
IPSP.
Whole-cell patch-clamp recording of miniature inhibitory
postsynaptic currents (mIPSCs)
We recorded from CeA neurons visualized in brain slices
(300 µm) using infrared differential interference contrast (IR-
DIC) optics and CCD camera (EXi Aqua, QImaging) (Gilpin
et al., 2011; Cruz et al., 2012; Herman et al., 2013). A w60
water immersion objective (Olympus) was used to identify and
approach the CeA neurons. Whole-cell voltage-clamp record-
ings were made with a Multiclamp 700B amplifier (Molecular
Devices), low-pass filtered at 2–5 kHz, digitized (Digidata 1440A;
Molecular Devices), and stored on a PC using pClamp 10 soft-
ware (Axon Instruments). All voltage-clamp were performed in
a gap-free acquisition mode with a sampling rate per signal of
10 kHz. Patch pipettes (4–8 M′) were pulled from borosilicate
glass (Warner Instruments) and filled with an internal solution
composed of (in mM): 145 KCl; 0.5 EGTA; 2 MgCl2; 10 HEPES;
2 Na-ATP; 0.2 Na-GTP. GABAergic miniature IPSCs (mIPSCs)
were recorded in the presence of 20 µM DNQX, 30 µM DL-AP5,
1 µM CGP 55845A and 1 µM tetrodotoxin (TTX). Drugs were
constituted in ACSF and applied by bath superfusion. All 12 cells
were clamped at −60 mV for the duration of the recording. In
all experiments, series resistance (<10 M′) was continuously
monitored with a 10 mV hyperpolarizing pulse and experiments
with >20% changes in series resistance were not included in
final analysis. Frequency, amplitude and kinetics of mIPSCs were
analyzed using a semi-automated threshold based mini detection
software (Mini Analysis, Synaptosoft Inc., Fort Lee, NJ) and were
visually confirmed. To accurately determine the mIPSC ampli-
tude, only mIPSCs with >5 pA were accepted for analysis. The
choice of this cutoff amplitude for acceptance of mIPSCs was
made to obtain a high signal-to-noise ratio. Averages of mIPSC
characteristics were based on a minimum time interval of 3–
5 min and a minimum of 50 events. All detected events were
used for event frequency analysis, but superimposed events were
eliminated for amplitude and decay kinetic analysis. All data are
expressed as mean± SEM.
Drugs
CGP 55845A, DL-AP5, picrotoxin and bicuculline were
purchased from Sigma (St. Louis, MO), TTX was purchased
from Biotum (Hayward, CA); DNQX and [Nphe1]Nociceptin(1–
13)NH2 from Tocris (Ellisville, MO) and ethanol from Remet
(La Mirada, CA). MT-7716, (R)-2-3-[1-(Acenaphthen-1-
yl)piperidin-4-yl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl-N-
methylacetamide hydrochloride hydrate, was synthesized at
Mitsubishi Tanabe Pharma Corporation (Japan). It was dissolved
in distilled water.
Data analysis and statistics
To analyze data acquired from intracellular and whole cell record-
ings, Clampfit 8.2 (Molecular Devices) and MiniAnalysis 5.1
software (Synaptosoft, Leonia, NJ) were respectively used.
GraphPad Prism 5.0 software (GraphPad Software, San Diego,
CA) and Statistica Package were employed for all statistical
analysis of results obtained by intracellular recording and for
figure presentations. Statistical significance was set at p < 0.05
level, using one-way ANOVA, Student’s t-test or one-sample
t-test/Wilcoxon signed rank test. T-test analysis was used for indi-
vidual means comparisons and within-subject one-way repeated
measures (RM) ANOVA to compare IPSPs within a group.
When appropriate, Newman-Keuls post-hoc test was used to
assess significance between treatments with p ≤ 0.05 considered
significant.
The mIPSC results were evaluated with cumulative probability
analysis, and statistical significance was determined using the
Kolmogorov-Smirnov, non-parametric two-sample test with p <
0.05 considered significant for each neuron. The pooled data from
all 12 CeA neurons studied were then analyzed by paired t-test
analysis for individual means comparisons to evaluate MT-7716
effects.
RESULTS
MT-7716 DECREASED EVOKED GABAERGIC TRANSMISSION IN
CENTRAL AMYGDALA(CeA) NEURONS
We recorded from 81 CeA neurons from male Wistar rats. The
mean RMP was−78± 1.7 mV and the mean input resistance was
115 ± 5 M. We evoked pharmacologically isolated GABAA-IPSPs
by stimulating locally within the CeA and IPSP input-output
(I/O) curves were generated. Based on our previous electrophysi-
ological data on N/OFQ (Roberto and Siggins, 2006) we generated
a dose-response curve testing four ranged concentrations (100
nM, 250 nM 500 nM and 1 µM) of MT-7716 on the mean
amplitude of evoked IPSPs in CeA neurons from naïve-control
rats (Figures 1A, B). We applied MT-7716 on CeA slices for
15–20 min and washed out for more than 25 min, until partial
or complete recovery was obtained. In Figure 1B, we expressed
the data as percent of control using the middle stimulus intensity
obtained from the I-O relationship. The graphs in Figures 2A–D
plot the percentage effect of MT-7716 on the IPSP amplitude for
the three stimulus intensities and the washout.
Although, the lowest (100 nM) concentration of MT-7716
tested, only slightly decreased the mean amplitude of evoked
IPSPs to 91 ± 4% of control (n = 11, Figure 2A) over the three
middle intensities, it did significantly decrease the amplitude of
IPSPs evoked by the half maximal intensity. Notably, 250 nM MT-
7716 significantly decreased the amplitude of evoked IPSPs to 78
± 7% (n = 10) with complete recovery after washout (Figure 2B).
Similarly, in another 11 CeA neurons, application of 500 nM MT-
7716 decreased significantly the mean evoked IPSP amplitudes
to 78 ± 3% (Figure 2C). This MT-7716 induced decrease of
evoked IPSP amplitude was reversible after washout in all the
above listed experiments. The highest concentration of MT-7716
tested (1 µM), significantly decreased the mean amplitude of
evoked GABA IPSPs to 80± 3% of control over the three-stimulus
intensities in 12 cells (Figure 2D).
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FIGURE 1 | MT-7716 decreases evoked GABAergic transmission in CeA
neurons. (A) Left panel: Representative recordings of evoked IPSPs in CeA
neurons from naïve rats recorded before, during, and after washout from
application of MT-7716 at all the concentrations tested. (B) Right Panel:
Histograms representing the percent of the peak decrease in evoked (at half
max stimulus intensity) IPSP amplitudes during superfusion of different
concentrations (100, 250, 500, and 1000 nM) of MT-7716 and washout.
Overall ANOVA revealed that MT-7716 decreased statistically significantly the
IPSP amplitudes. Post hoc Newman-Keuls showed significant effect for all the
doses at half max stimulus intensity. (*) Indicates p < 0.01.
FIGURE 2 | The percentage effect of MT-7716 on the IPSP amplitude for
the three middle stimulus intensities. (A) In the CeA of control rats,
MT-7716 100 nM significantly (** p < 0.01) decreases the mean amplitude of
evoked IPSP over the middle stimulus strength intensity tested (n = 11).
(B) MT-7716 250 nM significantly decreases the mean amplitude of evoked
IPSP over the three middle stimulus strength intensities tested (n = 10) (* p <
0.05) and (** p < 0.01). (C–D) MT-7716 500 and 1000 nM significantly
decrease the mean amplitude of evoked IPSPs over the three middle stimulus
strength intensities tested (n = 11/12) (** p < 0.01) and (*** p < 0.001). All
data are expressed as % of control for three normalized stimulus strengths.
Student t-test was used to analyze the percentage effect of MT-7716 on the
IPSP amplitude.
To evaluate whether the effect of MT-7716 was occurring at the
pre- or postsynaptic locus, we determined changes in PPF ratio, a
measure inversely related to neurotransmitter release (Andreasen
and Hablitz, 1994; Bonci and Williams, 1997; Roberto et al.,
2003). In brief, in CeA neurons, 100 nM MT-7716 significantly
(n = 8; p < 0.05) increased 50 ms PPF ratio from 0.77 ± 0.09
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FIGURE 3 | MT-7716 decreases GABAergic transmission in CeA
neurons by decreasing GABA release. (A) Representative recordings
of PPF at both 50 (upper traces) and 100 (lower traces) ms in a CeA
neuron from naïve rat before and during superfusion of 250 nM
MT-7716. (B) Overall ANOVA revealed that MT-7716 (100 and 250 nM)
significantly increases the PPF ratio of evoked IPSPs using 50 ms
interstimulus intervals. MT-7716 (250 and 500 nM) significantly
increases the PPF ratio of evoked IPSPs using 100 ms interstimulus
intervals. (*) Indicates (p < 0.05) after appropriate Post-hoc
Newman-Keuls test.
to 1.31 ± 0.18 and slightly increased the 100 ms PPF ratio from
1.04 ± 0.10 to 1.26 ± 0.14 (Figures 3A, B). The intermediate
dose 250 nM MT-7716 significantly increased both 50 and 100
ms PPF ratio from 1.02 ± 0.08 and 1.2 ± 0.08 to 1.36 ± 0.13
and 1.63 ± 0.25 respectively, (p < 0.05 and p < 0.04), suggesting
decreased GABA release. MT-7716 500 nM did not alter the 50 ms
PPF ratio (baseline 1.16 ± 0.14; MT-7716 1.23± 0.12; n = 8),
but increased significantly the 100 ms PPF ratio (p < 0.05) from
0.94 ± 0.08 to 1.13 ± 0.08; n = 6). In 7 CeA neurons, MT-7716
(1000 nM) did not alter either PPF ratio 50 or PPF ratio 100 ms.
(PPF 50 ms: baseline 1.07± 0.24; MT-7716 1.07 ± 0.22; PPF 100
ms: baseline 1.13 ± 0.24; MT-7716 1.22 ± 0.26). In summary,
we found that MT-7716 at the doses of 100, 250 and 500 nM
significantly increased PPF ratios.
We also evaluated if different concentrations of MT-7716
would affect the passive membrane properties of CeA neurons of
male Wistar rats. Similar to our N/OFQ studies in Sprague Dawley
rats (Roberto and Siggins, 2006), we found that none of the
concentrations of MT-7716 used, altered the resting membrane
properties (Figures 4A–D). Current–voltage (I–V) relationship
analysis showed that MT-7716 at the four concentrations tested
had no significant effect on (RMP), conductance (Figures 4A–D),
or the number of action potentials upon depolarization across
the CeA neurons (Figures 4E, F). The mean of the RMPs and
input resistance of the four groups of CeA neurons tested in
the dose-dependent study was 80.7 ± 1.5 mV and 117 ± 7.6
MΩ, respectively. Specifically, the number of actions potentials
for neurons in response to 200 and 400 pA current injections
were: 3.2 ± 1.4 and 9.7 ± 1.8 during control and 3.1± 1.5 and
9.2 ± 1.8 during 100 nM MT-7716; 4.6 ± 1.1 and 11.8 ± 1.1
during control and 4.5 ± 1.1 and 12.2 ± 1.4 during 250 nM
MT-7716; 4.1 ± 0.9 and 10.9 ± 1.7 during control and 4.3 ±
1.6 and 11.3 ± 2.1 during 500 nM MT-7716; 2.5 ± 1.5 and
8.3 ± 2.4 during control and 2.5 ± 1.6 and 8.3 ± 2.8 dur-
ing 1000 nM MT-7716. Representative current clamp recordings
from a CeA neuron during control conditions (Figure 4E) and
application of 500 nM MT-7716 (Figure 4F) are illustrated in
Figure 4.
MT-7716 DECREASED SPONTANEOUS MINIATURE INHIBITORY
POSTSYNAPTIC CURRENTS (mIPSCs) IN CENTRAL AMYGDALA (CeA)
To further characterize the decreased GABA release induced by
MT-7716, we examined spontaneous mIPSCs using whole-cell
recordings in the presence of 1 µM TTX to eliminate action
potential-dependent release of neurotransmitter. Here we tested
MT-7716 at 500 nM, a maximal effective and reversible con-
centration, and found that MT-7716 significantly (p < 0.05)
decreased mIPSC frequency to 78.9 ± 5.3% of control (means:
control, 0.82 ± 0.3 Hz; MT-7716, 0.67 ± 0.3 Hz; n = 12)
with recovery during washout (0.75 ± 0.4 Hz) (Figures 5A, D).
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FIGURE 4 | MT-7716 has no effect on voltage-current relationships on
the CeA neurons. (A–D) I/V curves showing that MT-7716, in all doses
superfused (100–1000 nM) Overall ANOVA indicates that MT-7716 does not
modify the RMP of the CeA neurons (n = 6–11). (A) The mean RMPs for the
neurons tested with 100 nM MT-7716 was −81 ± 1.2 mV and was −80 ±
0.5 mV for those tested 250 nM MT-7716 (B). Similarly the RMPs of the 10
and 6 CeA neurons tested with 500 nM and 1000 nM MT-7716 was −81.5 ±
0.9 mV (C) and −81 ± 1.2 mV (D). (E) Representative current clamp
recordings of a CeA neuron (RMP = 80 mV; input resistance 113 M) during
control and 500 nM MT-7716 superfusion (F). Overall, MT-7716 did not
significantly affect the firing pattern or number of action potentials in our
CeA neuronal population.
MT-7716 significantly decreased the frequency of mIPSCs and
shifted the cumulative frequency distribution to longer inter-
event intervals (Figures 5A–C), indicating decreased presynaptic
GABA release. MT-7716 also significantly (p < 0.05) decreased
the amplitude to 90.15± 0.5% of control (means: control, 62.3±
2.7 pA; MT-7716, 56.06 ± 2.4 pA; n = 12; Figures 5A, B and D),
but not the decay or rise time of mIPSCs.
INTERACTION OF MT-7716 AND ETHANOL AT THE CENTRAL AMYGDALA
(CeA) GABAERGIC SYNAPSES
We have previously reported (Roberto et al., 2003) that 44 mM
ethanol (a maximally effective concentration) increases evoked
GABA IPSPs via increased GABA release in the CeA. We have also
documented that N/OFQ blocks this ethanol-induced facilitation
(Roberto and Siggins, 2006). In the present study we recapitu-
late that ethanol 44 mM significantly (p < 0.05) and reversibly
increases by 36 ± 3% (n = 6) the amplitude of evoked IPSPs
(Figures 6A–C). This ethanol-induced increase is associated with
a significant (p < 0.05) decrease in the PPF ratio of IPSPs (both
50 and 100 ms intervals; data not shown). We then examined
whether MT-7716 would block the ethanol-induced increase in
evoked GABAergic responses. In separate groups of CeA cells,
we applied MT-7716 at the doses of 100, 250 and 500 nM and
then co-applied 44 mM ethanol on the top (Figures 6B, C). In
Figures 6B the data are expressed as percent of control using the
three middle stimulus intensities (1–3X) obtained from the I-O
relationship. All three concentrations of MT-7716 used (100, 250
and 500 nM) significantly decreased IPSP amplitudes (half maxi-
mal intensity) and totally blocked the ethanol-induced facilitation
of IPSPs. Specifically, MT-7716 (500 nM) significantly (p< 0.001;
n = 7) reduced the amplitude of evoked IPSPs by 20% of control
over all stimulus strengths in the CeA neurons (Figure 6B). After
15–20 min of MT-7716 superfusion, co-application of ethanol
(44 mM) did not increase the evoked IPSP amplitude (72.9 ±
1.1% of control). MT-7716 effectively prevented the ethanol-
induced enhancement of IPSPs, and GABA transmission returned
to baseline levels upon washout (94± 10% of control; Figure 6D).
Of note is the fact that MT-7716 in lower doses, 250 and 100 nM
also decreased evoked IPSPs to 79 ± 8% (n = 6) and 100 nM to
90 ± 6% (n = 6) of control respectively and blocked ethanol-
induced increase of IPSPs (the IPSPs amplitude remained the
same 80 ± 10% and 83 ± 3% of control, respectively) with
total recovery on washout. Interestingly, although the lowest
concentration of 100 nM MT-7716 had no significant effect on
evoked IPSP amplitudes (p > 0.05) (10% decrease compared to
control), it still completely blocked the ethanol-induced increase
of IPSPs with total recovery on washout, suggesting that the anti-
ethanol actions of NOP activation were not due simply to a sum-
mation of opposing effects, but functionally independent effects
on GABA transmission. We did not test the highest concentration
Frontiers in Integrative Neuroscience www.frontiersin.org February 2014 | Volume 8 | Article 18 | 6
Kallupi et al. N/OFQ agonist blocks ethanol effects
FIGURE 5 | MT-7716 decreased spontaneous miniature inhibitory
postsynaptic currents (mIPSCs) in CeA. (A) Representative CeA
mIPSCs before, during the superfusion of 500 nM MT-7716 and washout.
(B) Mean ± SEM frequency, amplitude, rise and decay of mIPSCs for
CeA neurons from control rats. MT-7716 significantly (* p < 0.001)
decreased the mean mIPSC frequencies and amplitude. Statistical
significance * was set at p < 0.05 and calculated by Student’s t-test.
(C) Cumulative fractions calculated by Kolmogorov-Smirnov sample test
show that MT-7716 shifted the cumulative frequency to the right (in 11
out of 12 CeA neurons studied), indicating a longer inter-event interval
during its application, suggesting decreased GABA release.
(D) Cumulative fractions calculated by Kolmogorov-Smirnov sample test
show that MT-7716 shifted the cumulative frequency to the right (in 10
out of 12 CeA neurons studied). MT-7716 shifted the cumulative
amplitude to the left, indicating smaller mIPSC amplitudes, suggesting
postsynaptic site of action.
of MT-7716 because although the inhibition induced by 1000 nM
MT-7716 was comparable to the one obtained with 500 and
250 nM, this effect was only partially recovered upon washout,
data not shown.
To assess the effectiveness of MT-7716 in blocking the ethanol
effects, we reversed the order of drugs application: we first applied
ethanol and then added MT-7716. Acute application of ethanol
significantly (p < 0.05) increased to 137.1 ± 4.7% of control the
amplitude of evoked IPSPs over all stimulus strengths (Figure 6E)
in 5 CeA neurons and decreased 50 and 100 ms PPF ratios from
1.21 ± 0.17 and 1.31 ± 0.14, to 0.85 ± 0.08 and 0.92 ± 0.02,
respectively. Superfusion of MT-7716 500 nM in the presence of
ethanol significantly reduced the mean evoked IPSP amplitude to
91.3 ± 1.4% of control with recovery upon washout. MT-7716
effectively blocked the ethanol-induced enhancement of IPSPs,
and GABA transmission returned to baseline levels upon washout
(103.3 ± 9.2% of control. MT-7716 application in the presence
of ethanol, correlated with an increase in the 50 and 100 ms PPF
ratio to 1.25 ± 0.13 and 1.37 ± 0.17, respectively. These effects
returned to baseline values after washout.
To determine whether the MT-7716-induced inhibition
of evoked CeA GABAergic transmission occurs via NOP
activation we tested [Nphe1]Nociceptin(1–13)NH2, a puta-
tive selective NOP receptor antagonist (Roberto and Siggins,
2006; Cruz et al., 2012; Kallupi et al., 2013). Application of
[Nphe1]Nociceptin(1–13)NH2 (1µM) alone did not alter evoked
IPSPs (105.1 ± 4.6% of control over the three middle intensities;
n = 7; by paired t-test; Figure 6F). To verify that MT-7716
activate NOPs we applied 500 nM MT-7716 in the presence of
the antagonist and found that MT-7716 no longer decreased
the evoked IPSPs (Figure 6F). These data suggest lack of tonic
activity of the endogenous NOPs and MT-7716 exerts its effect
through NOPs. In 4 of the 7 cells, we also tested whether
concomitant application of [Nphe1]Nociceptin(1–13)NH2 and
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FIGURE 6 | Interactions of MT-7716 and ethanol at the CeA GABAergic
synapses. (A) Overall ANOVA for the analyze of the time course of the %
IPSP amplitude in CeA neurons during ethanol application per se shows that
ethanol significantly increases the amplitude of evoked IPSPs. (B) Histograms
representing the percent of the peak decrease in evoked (at half max
stimulus intensity) IPSP amplitudes during superfusion of MT-7716 at the
concentrations (100, 250 and 500 nM) alone, and in the presence of ethanol
44 mM on top. Newman-Keuls post-hoc test showed that MT-7716 decreased
significantly the evoked IPSP amplitudes and blocked the ethanol-induced
facilitation. (*) Indicates (p < 0.05) (**) indicates (p < 0.01). (C)
Representative evoked IPSPs recorded before and during MT-7716 (100–500
nM) and co application with ethanol and washout. (D) Time course of the
application of MT-7716 (500 nM) that reduces the amplitude of evoked IPSPs.
After 15–20 min of MT-7716 superfusion, co-application of ethanol does not
increase the evoked IPSP amplitude (72.9 ± 1.1% of control). MT-7716
effectively blocks the ethanol-induced enhancement of IPSPs, and GABA
transmission returned to baseline levels upon 25 min of washout (94 ± 10%
of control). (E) Ethanol significantly (p < 0.05) increased (137.1 ± 4.7% of
control) the evoked IPSPs and 500 nM MT-7716 in the presence of ethanol
significantly (** p < 0.01 by Newman-Keuls post-hoc test) decreased (91.3 ±
1.4%) the IPSPs and blocked the ethanol-induced facilitation. (F) Application
of [Nphe1]Nociceptin(1–13)NH2 alone did not alter evoked IPSPs (105.1 ±
4.6% of control); n = 7; by paired t-test but blocked the MT-7716-induced
decrease of IPSPs.
MT-7716 affects ethanol-induced increases in evoked IPSPs.
We found that MT-7716 in the presence of the NOP antag-
onist did not prevent the 44 mM ethanol-induced augmen-
tation of IPSPs (135.2 ± 5.6% of control at half maximal
stimulus intensity; n = 4; data not shown), confirming that NOP
antagonism blocks the MT-7716 inhibition of ethanol-induced
facilitation.
DISCUSSION
Alcohol consumption has been identified as an important risk
factor for illness, disability, and mortality (Greenfield et al.,
2009; Mohapatra et al., 2010). Because detoxification does not
stop the craving for alcohol, in rats, like in humans, recovery
is often difficult to maintain. There are a few drugs that have
been FDA-approved to reduce alcohol craving like Acamprosate
and Naltrexone (Koob et al., 2002; Mann et al., 2004; Dahchour
et al., 2005; Mann et al., 2008; Umhau et al., 2011; Spanagel
and Vengeliene, 2013), however the study of new therapeutics for
alcoholism is still in progress. Several lines of evidence suggest
that the N/OFQ system serves an important role in the regulation
of various aspects of abused drugs and points to NOP receptor
agonism as potentially beneficial for the treatment of anxiety and
addictions (Lambert, 2008; Gavioli and Calo, 2013; Witkin et al.,
2014).
The CeA, a nucleus predominantly composed of GABAergic
inhibitory neurons, is essential for playing a role in negative
reinforcement, in fact acute and chronic alcohol effects on
brain stress systems can refer, among others, the recruitment
of extrahypothalamic brain stress systems such as CeA (Koob,
2009; Martin-Fardon et al., 2010). We have previously docu-
mented that ethanol increases GABAergic synaptic transmission
in the CeA via increased presynaptic GABA release (Roberto
et al., 2003). Specifically, ethanol augments evoked inhibitory
postsynaptic currents (IPSCs), decreases (PPF) of evoked IPSCs,
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and increases the frequency of miniature inhibitory postsynaptic
currents (mIPSCs) in most CeA neurons, indicating that alcohol
increases GABA release. These electrophysiological findings were
also validated by in vivo microdialysis studies showing that in
vivo administration of ethanol via microdialysis probe produced
a dose-dependent increase in GABA release in the CeA dialysate
(Roberto et al., 2004a). Moreover, in dependent rats we found an
increased baseline GABA tone compared to the non-dependent
rats suggesting that acute and chronic ethanol increases GABA
release in CeA (Roberto et al., 2004a). The CeA contains high
concentrations of anti-stress neuropeptides, such as N/OFQ,
known for its role in regulating anxiety- and alcohol-related
behaviors (Schank et al., 2012). Previous studies have shown that
N/OFQ prevents and totally reverses both the acute alcohol- and
CRF-induced increases in evoked IPSC amplitudes and mIPSC
frequencies opposing ethanol and CRF effects on GABA release
at presynaptic site (Roberto and Siggins, 2006; Cruz et al., 2012;
Ciccocioppo et al., 2014). Notably, the N/OFQ/NOP system is
upregulated in CeA of ethanol-dependent rats compared to naïve
controls, pointing to significant neuroadaptative changes induced
by chronic ethanol exposure (Roberto and Siggins, 2006; Cruz
et al., 2012). Altogether these data strongly suggest the potential
of NOP agonism as a suitable approach to treat alcohol addiction.
Hence, availability of small brain penetrant NOP agonists is
avidly awaited to further confirm the evidence obtained with
the endogenous ligand. The first nonpeptidergic brain-penetrant
NOP receptor agonists developed, Ro 61-6198 (Jenck et al., 2000)
and W-212393 (Teshima et al., 2005), were tested on rat alcohol-
related behaviors (Economidou et al., 2006; Kuzmin et al., 2007)
and circadian body temperature rhythm, respectively. Recently,
a new NOP agonist, namely MT-7716, with a pharmacological
profile suitable with clinical development has been synthesized.
Binding and functional studies showed a high affinity and selec-
tivity for NOP receptors. To further clarify the pharmacology of
MT-7716 here we characterized its effects on the neuronal level in
the CeA, comparing it with the known effects of N/OFQ in the
neuronal CeA. Our results demonstrated that MT-7716 reduces
evoked and spontaneous GABAergic transmission in the CeA
neurons evoked by electrical stimulation in a dose dependent
manner. Interestingly, the effects of MT-7716 are reversible as
the GABAergic response returned to control levels after washout
for all doses of the MT-7716 used, except for the highest one.
Moreover, the MT-7716-induced decrease of evoked IPSP ampli-
tude was observed in the majority (90%) of the neurons studied.
Generally, MT-7716 significantly increased PPF ratios suggesting
a presynaptic effect of the N/OFQ agonist on GABA release. This
presynaptic effect of MT-7716 was confirmed by the significant
decrease of the frequency of mIPSCs observed during MT-7716
superfusion. Importantly, the data obtained with the novel non-
peptidergic NOP agonist, are similar to our previous results
using N/OFQ that dose-dependently decreased CeA GABAergic
transmission, acting mostly presynaptically (Roberto and Siggins,
2006; Cruz et al., 2012).
Interestingly MT-7716, like N/OFQ reduced the mean
frequency of mIPSCs, but showed a decrease of the ampli-
tude as well, suggesting postsynaptic effects of MT-7716. Of
note is that the synthetic NOP agonist MT-7716 like N/OFQ
did not alter the resting membrane properties in any of
the doses used, which suggests a lack of an effect on the
mechanisms responsible for maintaining the RMP. In addi-
tion, MT-7716 did not alter the number of action potentials
upon depolarization at any of the four concentrations tested.
Importantly, [Nphe1]Nociceptin(1–13)NH2, a putative selec-
tive NOP antagonist totally prevented the MT-7716-induced
inhibition of IPSP amplitudes indicating that MT-7716 exerts
its effect through NOPs. Similarly, in our previous studies
with N/OFQ, this same NOP antagonist blocked the N/OFQ-
induced inhibition of GABAergic (Roberto and Siggins, 2006)
and glutamatergic (Kallupi et al., 2013) responses. Application
of the NOP antagonist did not affect the basal CeA GABAergic
transmission and the ethanol-induced increase in GABAergic
responses.
Finally, several lines of research have evaluated the effect
of N/OFQ on ethanol-related phenomena. The activation of
the NOP receptors blunts the reinforcing effects of alcohol like
alcohol intake (Ciccocioppo et al., 1999), relapse to alcohol
seeking (Martin-Fardon et al., 2000; Ciccocioppo et al., 2004) and
conditioned place preference (Kuzmin et al., 2003). Moreover, at
cellular levels, here we recapitulated that ethanol increases evoked
GABA IPSPs via increased GABA release in CeA (Roberto et al.,
2003), and demonstrated that the novel, synthetic nonpeptider-
gic NOP agonist, MT-7716 is effective in decreasing GABAergic
transmission and blocking the enhancement of GABA responses
induced by a maximal dose of ethanol 44 mM. In addition,
MT-7716 efficiently prevented the ethanol induced increase in
GABA release when applied first, and reversed the effect of
ethanol when co-applied with ethanol. Thus, our data show
that MT-7716, like N/OFQ, efficiently acts on the GABAergic
release in CeA and opposes ethanol effects at these synapses
providing rationale for developing novel therapeutics for alco-
holism. Collectively, the results of our investigation will lead
to a better understanding of the potential utility of employing
small molecule modulators of NOP to help treat alcoholism
and create the opportunity to explore the impact of manip-
ulations of the N/OFQ system on physiological function and
integrated disease-related functional correlates. Although a few
NOP agonists as small molecules have been put into clinical
play (Witkin et al., 2014), no clinical findings are currently
available to confirm or refute hypotheses based upon preclinical
evidence. Moreover, the development of other small molecules
in order to penetrate the blood brain barrier, and able to elicit
long lasting effects, is necessary to further investigate the alco-
hol effects in animal models and to perform controlled clinical
trials.
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